Overview of currently available benzodiazepine and non-benzodiazepine hypnotics

Clinical pharmacology of sleep

Volumn 9783764374402, Issue , 2006, Pages 207-223

  Monti, Jaime M ^a   Monti, Daniel ^b  

^a HOSPITAL DE CLÍNICAS   (Uruguay)

^b ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 35649003784     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/3-7643-7440-3_14     Document Type: Chapter

References (87)

1. Webb WB (1971) Sleep behavior as a biorhythm. In: WP Colquehoun (ed): Biological rhythms and human performance. Academic Press, New York, 149-177
2. Monti JM (1981) Sleep laboratory and clinical studies of the effects of triazolam, flunitrazepam and flurazepam in insomniac patients. Meth Find Exptl Clin Pharmacol 3:303-326
3. Hirshkowitz M (2004) Normal human sleep: an overview. Med Clin N Am 88:551-565
4. Williams RL, Karacan I, Thornby JI, Salis PJ (1972) The electroencephalogram sleep patterns of middle-aged males. J Nerv Ment Dis 154:22-30
5. Gillin JC, Duncan WC, Murphy DL, Post RM, Wehr TA, Goodwin FK, Wyatt RJ, Bunney WE (1981) Age-related changes in sleep in depressed and normal subjects. Psychiatry Res 4:73-78
6. Lauer CJ, Riemann D, Wiegand M, Berger M (1991) From early to late adulthood changes in EEG sleep of depressed patients and healthy volunteers. Biol Psychiatry 29:979-993
7. Ohayon MM, Carskadon MA, Guilleminault C, Vitiello MV (2004) Meta-analysis of quantitative sleep parameters from childhoodto old agein healthy individuals: Developing normative sleep values across the human lifespan. Sleep 27:1255-1273
8. National Sleep Foundation (2002) "2002 Sleep in America" Poll. Washington, D. C., 1-43
9. Foley DJ, Monjan AA, Brown SL, Simonsick EM, Wallace RB, Blazer DG (1995) Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep 18:425-432
10. Foley DJ, Monjan A, Izmirlian G, Hays JC, Blazer DG (1999) Incidence and remission of insomnia among elderly adults in a biracial cohort. Sleep (Suppl 2): S373-S378
11. American Sleep Disorders Association (1997) International classification of sleep disorders, revised: Diagnostic and coding manual. American Sleep Disorders Association, Rochester
12. Hohagen F, Kappler C, Schramm E, Riemann D, Weyerer S, Berger M (1994) Sleep onset insomnia, sleep maintaining insomnia and insomnia with early morning awakening - temporal stability of subtypes in a longitudinal study on general practice attenders. Sleep 17:551-554
13. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). American Psychiatric Association, Washington, D. C.
14. Lichstein KL (2000) Secondary insomnia. In: KL Lichstein, CM Morin (eds): Treatment of late-life insomnia. Sage Publications, London, 297-319
15. McCrae CS, Lichstein KL (2001) Secondary insomnia: diagnostic challenges and intervention opportunities. Sleep Med Rev 5:47-61
16. Paul SM (1995) GABA and glycine. In: FE Bloom, DJ Kupfer (eds): Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York, 87-94
17. Graham D, Besnard F, Faure C, Langer SZ (1996) GABAA receptor subtype diversity: Implications for new generation hypnotic drug discovery. Sleep 19:S43-S45
18. Teuber L, Watjen F, Jensen LH (1999) Ligands for the benzodiazepine binding side - a survey. Curr Pharm Design 5:317-343
19. Ator NA, McCann UD (2005) New insights into the GABAA receptor. CNS Spectrums 10:20
20. Charney DS, Mihic SJ, Harris RA (2001) Hypnotics and sedatives. In: JG Hardman, LE Limbird (eds): The Pharmacological Basis of Therapeutics. McGraw-Hill, New York, 399-427
21. Greenblatt DJ (1991) Benzodiazepine hypnotics: sorting the pharmacokinetic facts. J Clin Psychiatry 52(Suppl):4-10
22. Gaillot J, Heusse D, Houghton D, Aurele JM, Dreyfus J (1983) Pharmacokinetics and metabolism of zopiclone. Pharmacology 27(Suppl 2):76-91
23. Drover DR (2004) Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives. Clin Pharmacokinet 43:227-238
24. Musch B, Maillard F (1990) Zopiclone, the third generation hypnotic: a clinical overview. Int Clin Psychopharmacol 5(Suppl 2):147-158
25. Carlson JN, Haskew R, Wacker J, Maisonneuve IM, Glick SD, Jerussi TP (2001) Sedative and anxiolytic effects of zopiclone's enantionmers and metabolite. Eur J Pharmacol 415:181-189
26. Fernández C, Alt P, Davrinche C, Adrien J, Thuillier A, Farinotti R, Gimenez F (2002) Stereoselective distribution and stereoconversion of zopiclone enantiomers in plasma and brain tissues in rats. J Pharm Pharmacol 54:335-340
27. Thénot JP, Hermann P, Durand A, Burke JT, Allen J, Garrigou D, Vajta S, Albin H, Thébault JJ, Olive G et al (1988) Pharmacokinetics and metabolism of zolpidem in various animal species and in humans. In: JP Sauvanet, SZ Langer, PL Morselli (eds): Imidazopyridines in Sleep Disorders: A novel Experimental and Therapeutic Approach. Raven Press, New York, 139-163
28. Hurst M, Noble S (1999) Zaleplon. CNS Drugs 11:387-392
29. Rosen AS, Fournie P, Darwish M, Danjou P, Troy SM (1999) Zaleplon pharmacokinetics and absolute bioavailability. Biopharm Drug Dispos 20:171-175
30. Kaplan SA, Jack ML (1983) Metabolism of benzodiazepines: Pharmacokinetic and pharmacodynamic considerations. In: E Costa (ed): The Benzodiazepines: From Molecular Biology to Clinical Practice. Raven Press, New York, 173-199
31. Meyer BR (1982) Benzodiazepines in the elderly. Med Clin N Am 66:1017-1035
32. Wilkinson GR (1979) The effect of aging on the disposition of benzodiazepines in man. In: J Crooks, IH Stevenson (eds): Drugs and the Elderly: Perspectives in Geriatric Clinical Pharmacology. University Park Press, Baltimore, 103-116
33. Klotz U, Avant GR, Hoyumpa A, Schenker S, Wilkinson GR (1975) The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest 55:347-359
34. Noble S, Langtry HD, Lamb H M (1998) Zopiclone: An update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia. Drugs 55:277-302
35. Fernandez C, Martin C, Gimenez F, Farinotti R (1995) Clinical pharmacokinetics of zopiclone. Clin Pharmacokinet 29:431-441
36. Bianchetti G, Dubruc C, Thiercelin JF, Bercoff E, Bouchet JL, Emeriau JP, Galperine I, Lambert D, Vandel B, Thébault JJ (1988) Clinical pharmacokineticsofzolpidem invarious physiological and pathological conditions. In: JP Sauvanet, SZ Langer, PL Morselli (eds): Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach. Raven Press, New York, 155-163
37. Pacifici C, Viani A, Rizzo G, Carrai M, Ganansia J, Bianchetti G, Morselli PL (1988) Plasma protein binding of zolpidem in liver and renal insufficiency. Int J Clin Pharmacol Ther Toxicol 26:439-443
38. Darwish M (1999) The relationship between the pharmacokinetics and pharmacodynamics of zaleplon. Eur Neuropsychopharmacol 5(Suppl):S361
39. Drover DR (2004) Comparative pharmacokinetics and pharmacodynamicsofshort-acting hypnosedatives. Clin Pharmacokinet 43:227-238
40. Wickland C, Patat A (1999) The safety and pharmacokinetics of zaleplon in hepatically impaired patients. Sleep Res 2(Suppl 1):171
41. Monti JM, Boussard M, Olivera S, Labraga P, Alvariño F (1993) The effect of midazolam on transient insomnia. Eur J Clin Pharmacol 44:525-527
42. Monti JM, Monti D, Estévez F, Giusti M (1996) Sleep in patients with chronic primary insomnia during long-term zolpidem administration and after its withdrawal. Int Clin Psychopharmacol 11:255-263
43. Asnis GM, Chakraburtty A, Du Boff EA, Krystal A, Londborg PD, Rosenberg R, Roth-Schechter B, Scharf MB, Walsh JK (1999) Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry 60:668-676
44. Kales A, Kales JD (1984) Evaluation and Treatment of Insomnia. Oxford University Press, New York
45. Monti JM, Alterwain P, Debellis J, Altier H, Pellejero T, Monti D (1987) Short-term sleep laboratory evaluation of midazolam in chronic insomniacs. Arzneim-Forsch/Drug Res 37:54-57
46. Bixler EO, Kales A, Soldatos CR, Scharf MB, Kales JD (1978) Effectivenesoftemazepam with short-, intermediate-, and long-term use: sleep laboratory evaluation. J Clin Pharmacol 18:110-118
47. Kales A, Bixler EO, Soldatos CR, Vela-Bueno A, Jacoby J, Kales JD (1982) Quazepamand flurazepam: long-term use and extended withdrawal. Clin Pharmacol Ther 32:781-788
48. Mamelak M, Csima A, Price V (1984) A comparative 25-night sleep laboratory study of the effects of quazepam and triazolam on chronic insomniacs. J Clin Pharmacol 24:67-77
49. Mitler MM, Seidel BA, van den Hoed J, Greenblatt DJ, Dement WC (1984) Comparative hypnotic effects of flurazepam, triazolam, and placebo: a long-term simultaneous nighttime and daytime study. J Clin Psychopharmacol 4:2-13
50. Monti JM, Attali P, Monti D, Zipfel A, de la Giclais B, Morselli PL (1994) Zolpidem and rebound insomnia - a double-blind, controlled polysomnographic study in chronic insomniac patients. Pharmacopsychiatry 27:166-175
51. Kales A, Bixler EO, Soldatos CR, Vela-Bueno A, Jacoby JA, Kales JD (1986) Quazepam and temazepam: effects of short- and intermedaite-term use and withdrawal. Clin Pharmacol Ther 30:345-352
52. Vgontzas AN, Kales A, Bixler EO, Myers DC (1994) Temazepam 7.5 mg: effects on sleep in elderly insomniacs. Eur J Clin Pharmacol 46:209-213
53. Soldatos CR, Dikeos DG, Whitehead A (1999) Tolerance and rebound insomnia with rapidly eliminated hypnotics: a meta-analysis of sleep laboratory studies. Int Clin Psychopharmacol 14:287-303
54. Mamelak M, Csima A, Price V (1983) Effects of zopiclone on the sleep of chronic insomniacs. Pharmacology 27:156-164
55. Petre Quadens O, Hoffman G, Buytaert G (1983) Effects of zopiclone as compared to flurazepam on sleep in women over 40 years of age. Pharmacology 27 (Suppl 2) 146-155
56. Pecknold J, Wilson R, Le Morvan P (1990) Long-term efficacy and withdrawal of zopiclone: a sleep laboratory study. Int Clin Psychopharmacol 5:57-67
57. Tiberge M, Calvet U, Khayi N, Delahye C, Arbus L (1988) Comparison of the effects of zopiclone and triazolam on sleep in healthy subjects. Encephale 14:319-324
58. Billiard M, Besset A, De Lustrac C, Brissaud L, Cadilhac J (1989) Effect of zopiclone on sleep, daytime somnolence and nighttime performances in healthy volunteers. Neurophysiol Clin 19:131-143
59. Jovanovic UJ, Dreyfuss JF (1983) Polygraphical sleep recording in insomniac patients under zopiclone or nitrazepam. Pharmacology 27:136-145
60. Rosenberg R, Caron J, Roth T, Amato D (2005) An assessmentof the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults. Sleep Med 6:15-22
61. Zammit GK, McNabb LJ, Caron J, Amato DA, Roth T (2004) Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 20:1979-1991
62. Krystal AD, Walsh JK, Laska E, Caron J, Amato DA, Wessel TC, Roth T (2003) Sustained efficacy of eszopiclone over 6 months of nightly treatment: Results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 26:793-799
63. Nicholson AN, Pascoe PA (1986) Hypnotic activity of an imidazopyridine (zolpidem). Brit J Clin Pharmacol 21:205-211
64. Herrmann WM, Dubicki S, Wober W (1988) Zolpidem: a four week pilot polysomnographic study in patients with chronic sleep disturbances. In: JP Sauvanet, SZ Langer, PL Morselli (eds): Imidazopyridines in Sleep Disorders: a Novel Experimental and Therapeutic Approach. Raven Press, New York, 261-278
65. Monti JM (1989) Effects of zolpidem on sleep in insomniac patients. Eur J Clin Pharmacol 36:461-466
66. Perlis ML, McCall WV, Krystal AD, Walsh JK (2004) Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. J Clin Psychiatry 65:1128-1137
67. Roger M, Dallot JY, Salmon O, Neveux E, Gitton JP, Gerson M, Brossel S, Sauvanet JP (1988) Hypnotic effect of zolpidem in geriatric patients: A dose-finding study. In: Sauvanet JP, Langer SZ, Morselli PL (eds): Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach. Raven Press, New York, 279-287
68. Sauvanet JP, Maarek L, Roger M, Renaudin J, Louvel E, Orofiamma B (1988) Open longterm trials with zolpidem in insomnia. In: JP Sauvanet, SZ Langer, PL Morselli (eds): Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach. Raven Press, New York, 339-349
69. Benoit O, Bouard G, Payan C, Prado J, Blanchet G (1994) Effect of a single dose (10 mg) of zolpidem on visual and spectral analysis of sleep in young poor sleepers. Psychopharmacology 116:297-303
70. Monti JM, Alvariño F, Monti D (2000) Conventional and power spectrum analysis of the effects of zolpidem on sleep EEG in patients with chronic primary insomnia. Sleep 23:1075-1084
71. Heydorn WE (2000) Zaleplon - a review of a novel sedative hypnotic used in the treatment of insomnia. Exp Opin Invest Drugs 9:841-858
72. Walsh JK, Vogel GW, Scharf M, Erman M, Erwin CW, Schweitzer PK, Mangano RM, Roth T (2000) A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med 1:41-49
73. Elie R, Ruther E, Farr I, Emilien G, Salinas E (1999) Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel non-benzodiazepine hypnotic. J Clin Psychiatry 60:536-544
74. Bixler EO, Scharf MB, Soldatos CR, Mitsky DJ, Kales A (1979) Effects of hypnotic drugs on memory. Life Sci 25:1379-1388
75. Bixler EO, Kales A, Manfredi RL, Vgontzas AN, Tyson KL, Kales JD (1991) Next-day memory impairment with triazolam use. Lancet 337:827-831
76. Adam K, Oswald I (1989) Can a rapidly-eliminated hypnotic cause daytime anxiety? Pharmacopsychiatry 22:115-119
77. Hindmarch I, Haller J, Sherwood N, Kerr JS (1990) Comparison of five anxiolytic benzodiazepines on measures of psychomotor performance and sleep. Neuropsychobiology 24:84-89
78. Lader M (1994) Anxiety or depression during withdrawal of hypnotic treatments. J Psychosom Res 38 (Suppl 1) 113-123
79. Trewin VF, Lawrence CJ, Veitch GB (1992) An investigation of the association of benzodiazepines and other hypnotics with the incidence of falls in the elderly. J Clin Pharm Ther 17:129-133
80. Allain H, Delahaye C, Le Coz F, Blin P, Decombe R, Martinet JP (1991) Postmarketing surveillance of zopiclone in insomnia: analysis of 20513 cases. Sleep 14:408-413
81. Kuitunen T, Mattila MJ, Seppala T (1990) Actions and interactions ofhypnotics on human performance: single doses of zopiclone, triazolam and alcohol. Int Clin Psychopharmacol 5 (Suppl 2) 115-130
82. Holm KJ, Goa KL (2000) Zolpidem - An update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 59:865-889
83. Monti JM (2004) Primary and secondary insomnia: Prevalence, causes and current therapeutics. Curr Med Chem - CNS Agents 4:119-137
84. Zhdanova IV (2004) Advances in the management of insomnia. Expert Opin Pharmacother 5:1573-1579
85. Sateia MJ, Pigeon WR (2004) Identification and management of insomnia. Med Clin N Am 88:567-596
86. Cluydts R, Peeters K, de Bouyalski I, Lavoisy J (1998) Comparison of continuous versus intermittent administration of zolpidem in chronic insomniacs: a double-blind, randomized pilot study. J Int Med Res 26:13-24
87. Hajak G, Cluydts R, Allain H, Estivill E, Parrino L, Terzano MG, Walsh JK (2003) The challenge of chronic insomnia: is non-nightly hypnotic treatment a feasible alternative? Eur Psychiatry 18:201-208